您的位置: 首页 > 农业专利 > 详情页

RÉGIME POSOLOGIQUE POUR LA SAPACITABINE ET LA DÉCITABINE EN ASSOCIATION POUR LE TRAITEMENT DE LA LEUCÉMIE MYÉLOÏDE AIGUË
专利权人:
Cyclacel Limited
发明人:
申请号:
EP19176614.6
公开号:
EP3560501A1
申请日:
2012.04.13
申请国别(地区):
EP
年份:
2019
代理人:
摘要:
A first aspect of the invention relates to a method of treating AML in a subject, said method comprising administering to a subject a therapeutically effective amount of (i) sapacitabine, or a metabolite thereof; and (ii) decitabine; in accordance with a dosing regimen comprising at least one first treatment cycle and at least one second treatment cycle,wherein said first treatment cycle comprises administering a therapeutically effective amount of decitabine for 5 to 10 consecutive days followed by a rest period of from 3 to 5 weeks, or until treatment-related toxicities are resolved, whichever is longer; andwherein said second treatment cycle comprises administering a therapeutically effective amount of sapacitabine, or a metabolite thereof, for 3 consecutive days per week, for 2 weeks followed by a rest period of from 2 to 4 weeks, or until treatment-related toxicities are resolved, whichever is longer.
来源网站:
中国工程科技知识中心
来源网址:
http://www.ckcest.cn/home/

意 见 箱

匿名:登录

个人用户登录

找回密码

第三方账号登录

忘记密码

个人用户注册

必须为有效邮箱
6~16位数字与字母组合
6~16位数字与字母组合
请输入正确的手机号码

信息补充